Ionis (IONS) Q4 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Globe and Mail, The
Chief Development Officer — Holly Kordasiewicz Chief Commercial Officer — Kyle Jenne Chief Financial Officer — Elizabeth L. Hougen Chief Medical Officer — Eugene Schneider Executive Vice President, Research — Eric Swayze Need a quote from a Motley Fool analyst? Email pr@fool.com RISKS Elizabeth L. Hougen noted, "we expect a meaningful decline in TRYNGOLZA revenues throughout the year ahead of the sHTG launch," due to anticipated FCS revenue impacts prior to expansion. Guidance assumes standard FDA review timeline for olezarsen, limiting near-term sHTG revenue contributions if priority review is not granted. TAKEAWAYS Total revenue -- $944 million, a 34% increase year over year, driven by commercial product sales and R&D collaborations. Commercial product revenue -- $436 million, representing 46% of total revenue, with contributions from TRYNGOLZA and DAWNZERA. TRYNGOLZA sales -- $108 million for the year, including $50 million in the fourth quarter, a 56% quar
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals (IONS) had its "overweight" rating reaffirmed by Morgan Stanley.MarketBeat
- Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual MeetingBusiness Wire
- Ionis Pharmaceuticals (IONS) was given a new $110.00 price target by Canaccord Genuity Group Inc..MarketBeat
- How The Ionis Pharmaceuticals (IONS) Story Is Shifting With New Targets And 2026 Catalysts [Yahoo! Finance]Yahoo! Finance
- Ionis to hold first quarter 2026 financial results webcastBusiness Wire
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 4/21/26 - Form 8-K
- 4/17/26 - Form 4
- 4/17/26 - Form 4
- IONS's page on the SEC website